CALUMET INC (CLMT) Forecast, Price Target & Analyst Ratings
NASDAQ:CLMT • US1314281049
30.4 USD
+0.11 (+0.36%)
At close: Mar 6, 2026
30.4 USD
0 (0%)
After Hours: 3/6/2026, 8:08:34 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CALUMET INC (CLMT).
Forecast Snapshot
Consensus Price Target
$26.52
-12.76% Downside
Next Earnings Forecast
Release DateMay 7, 2026
PeriodQ1 / 2026
EPS Estimate-$0.36
Revenue Estimate1.041B
ChartMill Buy Consensus
78.33%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$26.52
Upside
-12.76%
From current price of $30.40 to mean target of $26.52, Based on 12 analyst forecasts
Low
$19.19
Median
$26.52
High
$34.65
Price Target Revisions
1 Month
19.20%
3 Months
19.20%
Price Target Summary
12 analysts have analysed CLMT and the average price target is 26.52 USD. This implies a price decrease of -12.76% is expected in the next year compared to the current price of 30.4.
The average price target has been revised upward by 19.2% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
78.33%
CLMT was analyzed by 12 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CLMT.
In the previous month the buy percentage consensus was at a similar level.
CLMT was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-30 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-11-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-22 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-08-12 | UBS | Maintains | Neutral -> Neutral |
| 2025-05-14 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-13 | B of A Securities | Initiate | Buy |
| 2025-04-30 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-03-17 | UBS | Upgrade | Sell -> Neutral |
| 2025-03-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-04 | UBS | Downgrade | Neutral -> Sell |
| 2025-01-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-11 | TD Cowen | Maintains | Buy -> Buy |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-21 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-10-17 | TD Cowen | Maintains | Buy -> Buy |
| 2024-10-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-12 | TD Cowen | Maintains | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-05 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 7, 2026
PeriodQ1 / 2026
EPS Estimate-$0.36
Revenue Estimate1.041B
Revenue Q2Q4.74%
EPS Q2Q86.12%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
3.85%
Revenue (3 Months)
4.25%
EPS (1 Month)
41.21%
EPS (3 Months)
21.13%
Next Earnings Summary
CLMT is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -0.36 USD and the consensus revenue estimate is 1.04B USD.
The next earnings revenue estimate has been revised upward by 4.25% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.687B 48.88% | 4.181B -10.79% | 4.189B 0.20% | 4.239B 1.18% | 4.325B 2.03% | 4.606B 6.50% | 5.297B 15.00% | 5.777B 9.06% | 6.06B 4.90% | 6.286B 3.73% | 6.508B 3.53% | 6.739B 3.55% | |
| EBITDA YoY % growth | 232.4M 793.85% | 417.5M 79.65% | 159.1M -61.89% | 290.85M 82.81% | 368.57M 26.72% | 457.08M 24.01% | 640.76M 40.19% | 851.7M 32.92% | 982.57M 15.37% | 1.07B 8.90% | 1.138B 6.36% | 1.194B 4.92% | |
| EBIT YoY % growth | 134.1M 264.14% | 270.7M 101.86% | 10.1M -96.27% | 182.04M 1,702.38% | 195.8M 7.56% | 211.49M 8.01% | 352M 66.44% | 483.07M 37.24% | 605.47M 25.34% | 684.11M 12.99% | 742.76M 8.57% | 789.07M 6.23% | |
| Operating Margin | 2.86% | 6.47% | 0.24% | 4.29% | 4.53% | 4.59% | 6.65% | 8.36% | 9.99% | 10.88% | 11.41% | 11.71% | |
| EPS YoY % growth | -2.04 -25.93% | 0.79 138.73% | -2.64 -434.18% | -0.41 57.95% | -0.87 21.89% | -0.07 92.35% | 1.38 2,176.92% | 2.26 64.44% | 2.91 28.38% | 3.60 23.86% | 4.14 15.01% | 4.60 11.08% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.36 86.12% | -0.01 99.40% | 0.07 -98.16% | -0.04 89.96% | -0.11 68.79% | 0.12 1,300.00% | 0.19 182.05% | 0.06 230.71% |
| Revenue Q2Q % growth | 1.041B 4.74% | 1.097B 6.86% | 1.176B 9.09% | 1.198B 15.35% | 1.239B 19.02% | 1.28B 16.68% | 1.318B 12.07% | 1.304B 8.85% |
| EBITDA Q2Q % growth | 71.257M 60.58% | 101.51M 66.09% | 116.56M 54.11% | 97.624M 29.83% | 93.35M 31.00% | 111.42M 9.76% | 117.56M 0.86% | 106.22M 8.81% |
| EBIT Q2Q % growth | 4.85M 104.37% | 50.474M 149.97% | 68.182M -79.29% | 38.25M 506.18% | 22.542M 364.78% | 47.226M -6.43% | 59.67M -12.48% | 38.964M 1.87% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
47.98%
EPS Next 5 Year
35.80%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
7.71%
Revenue Next 5 Year
7.41%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
276.55%
EBIT Next 5 Year
150.05%
CALUMET INC / CLMT Forecast FAQ
What is the average price target for CALUMET INC (CLMT) stock?
12 analysts have analysed CLMT and the average price target is 26.52 USD. This implies a price decrease of -12.76% is expected in the next year compared to the current price of 30.4.
What is the next earnings date for CLMT stock?
CALUMET INC (CLMT) will report earnings on 2026-05-07.
Can you provide the consensus estimates for CALUMET INC next earnings?
The consensus EPS estimate for the next earnings of CALUMET INC (CLMT) is -0.36 USD and the consensus revenue estimate is 1.04B USD.
What is the expected long term growth rate for CALUMET INC (CLMT)?
The expected long term growth rate for CALUMET INC (CLMT) is 7.71%.